PharmacoEconomics & Outcomes News 784, p36 - 12 Aug 2017 SMC approves three new medicines for NHS Scotland The Scottish Medicines Consortium (SMC) has approved three new medicines for routine use by NHS Scotland. Firstly, carfilzomib (Kyprolis) was accepted for use in combination with dexamethasone for the treatment of patients with multiple myeloma. Compared with other current treatments, carfilzomib has a more favourable adverse events profile and has been associated with increased overall and progression-free survival. Secondly, venetoclax (Venclyxto) was accepted by the SMC for the treatment of chronic lymphocytic leukaemia. Venetoclax can potentially improve quality of life and significantly reduce symptoms in this patient group, with participants in the consideration process emphasising that they have limited options when initial treatments fail or are unsuitable. Both carfilzomib and venetoclax were considered via SMC’s Patient and Clinician Engagement (PACE) process, which is used for medicines for very rare conditions. Lastly, the SMC accepted desmopressin for the treatment of idiopathic nocturnal polyuria. However, a lack of comparable cost effectiveness meant that 5-aminolaevulinic acid hydrochloride gel (Ameluz) was not approved for routine use by NHS Scotland for basal cell carcinomas that are unsuitable for surgical removal. "The company’s evidence on the economic benefits of the medicine compared to other similar treatments was not sufficient for us to accept it for routine use", commented Chairman of the SMC, Dr Alan MacDonald. Scottish Medicines Consortium. August 2017 decisions news release. Internet Document : 7 Aug 2017. Available from: URL: http:// www.scottishmedicines.org.uk/About_SMC/Latest_news/News_Articles/ August_2017_decisions_news_release 803263882 1173-5503/17/0784-0001/$14.95 Adis © 2017 Springer International Publishing AG. All rights reserved PharmacoEconomics & Outcomes News 12 Aug 2017 No. 784
PharmacoEconomics & Outcomes News – Springer Journals
Published: Aug 12, 2017
It’s your single place to instantly
discover and read the research
that matters to you.
Enjoy affordable access to
over 18 million articles from more than
15,000 peer-reviewed journals.
All for just $49/month
Query the DeepDyve database, plus search all of PubMed and Google Scholar seamlessly
Save any article or search result from DeepDyve, PubMed, and Google Scholar... all in one place.
Get unlimited, online access to over 18 million full-text articles from more than 15,000 scientific journals.
Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.
All the latest content is available, no embargo periods.
“Hi guys, I cannot tell you how much I love this resource. Incredible. I really believe you've hit the nail on the head with this site in regards to solving the research-purchase issue.”Daniel C.
“Whoa! It’s like Spotify but for academic articles.”@Phil_Robichaud
“I must say, @deepdyve is a fabulous solution to the independent researcher's problem of #access to #information.”@deepthiw
“My last article couldn't be possible without the platform @deepdyve that makes journal papers cheaper.”@JoseServera